A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Watanabe, Toshio ^a   Takeuchi, Toshihisa ^b   Handa, Osamu ^c   Sakata, Yasuhisa ^d   Tanigawa, Tetsuya ^a   Shiba, Masatsugu ^a   Naito, Yuji ^c   Higuchi, Kazuhide ^b   Fujimoto, Kazuma ^d   Yoshikawa, Toshikazu ^c   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; REBAMIPIDE; ALANINE; ANTIULCER AGENT; QUINOLONE DERIVATIVE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY; FEMALE; GASTROSCOPY; HUMAN; LOW DRUG DOSE; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH MUCOSA INJURY; STOMACH PROTECTION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANALOGS AND DERIVATIVES; CAPSULE ENDOSCOPY; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; INTESTINAL DISEASES; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SMALL INTESTINE; TREATMENT OUTCOME;

AGED; ALANINE; ANTI-ULCER AGENTS; ASPIRIN; CAPSULE ENDOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTESTINAL DISEASES; INTESTINE, SMALL; MALE; QUINOLONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84928905659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122330     Document Type: Article

References (30)

1. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300: 2134-2141. doi: 10.1001/jama.2008.623 PMID: 18997198
2. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293-1304. PMID: 15753114
3. Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One. 2014; 9: e90286. doi: 10.1371/journal.pone.0090286 PMID: 25360605
4. Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol. 2008; 6: 1279-1282. doi: 10.1016/j.cgh.2008.06.021 PMID: 18995219
5. Smecuol E, Pinto Sanchez MI, Suarez A, Argonz JE, Sugai E, Vazquez H, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 2009; 7: 524-529. doi: 10.1016/j.cgh.2008.12.019 PMID: 19249402
6. Nadatani Y, Watanabe T, Tanigawa T, Sogawa M, Yamagami H, Shiba M, et al. Incidence and risk factors of gastrointestinal bleeding in patients on low-dose aspirin therapy after percutaneous coronary intervention in Japan. Scand J Gastroenterol. 2013; 48: 320-325. doi: 10.3109/00365521.2012.758771 PMID: 23298342
7. Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011; 46: 894-905. doi: 10.1007/s00535-011-0410-1 PMID: 21556830
8. Watari I, Oka S, Tanaka S, Aoyama T, Imagawa H, Shishido T, et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol. 2013; 13: 108. doi: 10.1186/1471-230X-13-108 PMID: 23826914
9. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005; 50 Suppl 1: S3-S11. PMID: 16184418
10. Park SH, Cho CS, Lee OY, Jun JB, Lin SR, Zhou LY, et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr. 2007; 40: 148-155. doi: 10.3164/jcbn.40.148 PMID: 18188417
11. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008; 43: 270-276. doi: 10.1007/s00535-007-2155-4 PMID: 18458842
12. Mizukami K, Murakami K, Abe T, Inoue K, Uchida M, Okimoto T, et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011; 17: 5117-5122. doi: 10.3748/wjg.v17.i46.5117 PMID: 22171147
13. Akamatsu T, Nakamura N, Furuya N, Shimizu T, Gotou A, Kiyosawa K, et al. Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. Dig Dis Sci. 2002; 47: 1399-1404. PMID: 12064818
14. Gralnek IM, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008; 27: 146-154. PMID: 17956598
15. Tanigawa T, Watanabe T, Ohkawa F, Nadatani Y, Otani K, Machida H, et al. Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr. 2011; 48: 149-153. doi: 10.3164/jcbn.10-75 PMID: 21373268
16. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut. 2008; 57: 181-187. PMID: 17639086
17. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009; 44: 879-888. doi: 10.1007/s00535-009-0102-2 PMID: 19568687
18. Arakawa T, Watanabe T, Tanigawa T, Tominaga K, Otani K, Nadatani Y, et al. Small intestinal injury caused by NSAIDs/aspirin: finding new from old. Curr Med Chem. 2012; 19: 77-81. PMID: 22300079
19. Nadatani Y, Watanabe T, Tanigawa T, Machida H, Okazaki H, Yamagami H, et al. High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. Am J Pathol. 2012; 181: 98-110. doi: 10.1016/j.ajpath.2012.03.039 PMID: 22634181
20. Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009; 297: G506-513. doi: 10.1152/ajpgi.90553.2008 PMID: 19589943
21. Watanabe T, Tanigawa T, Shiba M, Nadatani Y, Nagami Y, Sugimori S, et al. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients. Gut. 2014; 63: 409-414. doi: 10.1136/gutjnl-2013-304713 PMID: 23697473
22. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010; 4: 261-270. doi: 10.1586/egh.10.25 PMID: 20528113
23. Watanabe T, Higuchi K, Taira K, Sasaki E, Shiba M, Tominaga K, et al. Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice. Dig Dis Sci. 2005; 50 Suppl 1: S63-69. PMID: 16184423
24. Sun WH, Tsuji S, Tsujii M, Gunawan ES, Kawai N, Kimura A, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000; 295: 447-452. PMID: 11046075
25. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci. 1998; 43: 160S-166S. PMID: 9753244
26. Watanabe T, Higuchi K, Hamaguchi M, Tanigawa T, Wada R, Tominaga K, et al. Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori infection in Mongolian gerbils. Dig Dis Sci. 2002; 47: 1582-1589. PMID: 12141820
27. Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993; 43: 363-366. PMID: 8387788
28. Nagano Y, Matsui H, Muramatsu M, Shimokawa O, Shibahara T, Yanaka A, et al. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig Dis Sci. 2005; 50 Suppl 1: S76-83. PMID: 16184425
29. Imaeda H, Fujimoto T, Takahashi K, Kasumi E, Fujiyama Y, Andoh A. Terminal-restriction fragment length polymorphism (T-RFLP) analysis for changes in the gut microbiota profiles of indomethacin- and rebamipide-treated mice. Digestion. 2012; 86: 250-257. doi: 10.1159/000341508 PMID: 22964750
30. Tanigawa T, Watanabe T, Otani K, Nadatani Y, Ohkawa F, Sogawa M, et al. Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of alpha-defensin 5. Eur J Pharmacol. 2013; 704: 64-69. doi: 10.1016/j.ejphar.2013.02.010 PMID: 23428631